News25/Ratings0
Latest news
25 items- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
- 13D/GSEC Form SC 13G/A filed by Obalon Therapeutics, Inc. (Amendment)SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)
- 13D/GSEC Form SC 13D/A filed by Obalon Therapeutics, Inc. (Amendment)SC 13D/A - ReShape Lifesciences Inc. (0001427570) (Subject)
- INSIDERSEC Form 4 filed by ARMISTICE CAPITAL, LLC4 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- 13D/GSEC Form SC 13D filed by Obalon Therapeutics, Inc.SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)
- INSIDERSEC Form 3: STANKOVICH THOMAS claimed ownership of 2,613 units of Common Stock3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3 filed by McDougal Lori Courtney3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3 filed by GLADNEY DAN W3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3 filed by MINOCHERHOMJEE ARDA PHD3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3 filed by Bandy Barton P.3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3 filed by BLACKFORD GARY3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 4: ARMISTICE CAPITAL, LLC sold $14,230,402 worth of Common Stock (2,303,469 units at $6.18)4 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- INSIDERSEC Form 3: ARMISTICE CAPITAL, LLC claimed ownership of 4,818,684 units of Common Stock3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Obalon Therapeutics, Inc. (Amendment)SC 13D/A - OBALON THERAPEUTICS INC (0001427570) (Subject)
- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
- PRReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of MergerSAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS."Immediately following the effective time of the merger, existing ReShape stockholders will own 51% and existing Obalon stockholders will own 49% of the outstanding shares of common stock of the
- PRReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending MergerSAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing). Upon the closing of the merger, shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital M
- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
- PRReminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape LifesciencesSAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.All stockholders are highly encouraged to vote by phone or email on this critical transaction. Without the required stockholder approval, the merger will not be able t
- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
- SECSEC Form 425 filed by Obalon Therapeutics, Inc.425 - OBALON THERAPEUTICS INC (0001427570) (Subject)
- PRObalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape LifesciencesSAN DIEGO, CA / ACCESSWIRE / May 21, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.All stockholders are highly encouraged to vote by phone or email on this critical transaction. Without the required stockholder approval, the merger will not be able t
- SECObalon Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
- SECSEC Form 425 filed by Obalon Therapeutics, Inc.425 - OBALON THERAPEUTICS INC (0001427570) (Subject)